11769 results for "cancer rna-seq"

in 16.53 milliseconds.

• Radboudumc Cancer Genomics DAC

  Dac EGAC00001001102

• Charbonneau Cancer Institute DAC

  Dac EGAC00001001165

• Charbonneau Cancer Institute DAC

  Dac EGAC00001001280

• Cancer Data Access Commitee

  Dac EGAC00001001436

• DAC Barretos Cancer Hospital

  Dac EGAC00001001592

• Spatial Characterization Breast Cancer

  Dac EGAC00001001673

• Gene expression and Cancer

  Dac EGAC00001001727

• Charbonneau Cancer Institute DAC

  Dac EGAC00001002096

• Breast cancer bone metastases

  Dac EGAC00001002771

• Breast cancer bone metastases

  Dac EGAC00001002772

• DAC Synergie Lyon Cancer

  Dac EGAC00001002795

• Breast cancer bone metastases

  Dac EGAC00001003035

• DAC - Pediatric Solid Cancer

  Dac EGAC00001003088

• Cancer Team Data Access Committee

  Dac EGAC00001003407

• Leukemia sequencing study

  Study EGAS00001006901

• Sequencing of Ovarian Cancer

  Study EGAS00001007489

• Sequencing of Breast Cancer

  Study EGAS00001007490

• DAC Barretos Cancer Hospital

  Dac EGAC50000000013

• ID1 in glioblastoma

  Study EGAS00001003711

• EAC Genomic data

  Study EGAS00001004887

• Pearl study

  Study EGAS00001005523

• Brain Cancer Center Committee

  Dac EGAC50000000456

• Lobular Carcinomas In Situ Display Intra-Lesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Disease

  This study comprises prospectively accrued, microdissected fresh frozen samples of multifocal lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), invasive lobular carcinoma and invasive ductal carcinoma from patients undergoing prophylactic or therapeutic mastectomies after a diagnosis on LCIS diagnosed and managed at Memorial Sloan Kettering Cancer Center (MSKCC). Microdissected samples were subjected to paired-end whole exome sequencing on an Illumina HiSeq 2000. The data generated were used to define the landscape of somatic genetic alterations of LCIS, DCIS, invasive lobular carcinoma and invasive ductal carcinoma, to define clonal relatedness of these lesions and to investigate the clonal shifts in the progression from in situ to invasive breast cancer.

  Study phs001006

• A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy

  The accurate identification and prioritization of antigenic peptides is crucial for the development of personalized cancer immunotherapies. Publicly available pipelines to predict clinical neoantigens do not allow direct integration of mass spectrometry immunopeptidomics data, which can uncover antigenic peptides derived from various canonical and non-canonical sources. To address this, we present an end-to-end clinical proteogenomic pipeline, called NeoDisc, that combines state-of-the-art publicly available and in-house software for immunopeptidomics, genomics and transcriptomics with in-silico tools for the identification, prediction, and prioritization of tumor-specific and immunogenic antigens from multiple sources, including neoantigens, viral antigens and high-confidence tumor-specific antigens.

  Study EGAS50000000228

• Fragmentomics analyses of urinary cell-free DNA permit multi-urologic cancer detection and reduction in tissue biopsies for prostate cancer

  This study demonstrated the close association between urinary cell-free DNA (cfDNA) methylation status and the fragmentation patterns in healthy controls and patients with various diseases. Fragmentomics-based methylation analysis (FRAGMA) enables accurate estimation of methylation levels in urinary cfDNA, which is proved by paired bisulfite sequencing and non-bisulfite sequencing data. FRAGMA showed high accuracy in deducing tissue-of-origin of urinary cfDNA in transplantation patients and pregnant women. Moreover, FRAGMA showed great potential in the detection and classification of multiple cancers from the urinary system, including bladder, kidney, and prostate cancer. This study demonstrated that FRAGMA could be applied to improve current diagnostic strategies based on urine samples.

  Study EGAS50000001431